NFKB1 and neoplasm: Some studies have also explored the combining NF-κB inhibitors with immune checkpoint inhibitors, revealing that NF-κB inhibition can enhance the anti-tumor immune response by reducing PD-L1 expression and promoting T-cell infiltration into TME.